翻訳と辞書 |
BioMS Medical Corp : ウィキペディア英語版 | Medwell Capital
Medwell Capital Corp. (formerly BioMS Medical Corp) () is a Canadian biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of Multiple Sclerosis. On July 27, 2009 the company announced that its drug, dirucotide, failed to meet its primary endpoint in the Phase III MAESTRO-01 Trial. It will discontinue testing of the drug and the future of the company is unclear. ==Development== Medwell Capital obtained an exclusive worldwide license to proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The compound, dirucotide (MBP8298), is a synthetic myelin basic protein peptide composed of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Medwell Capital」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|